Maurice Blackburn is investigating a possible class action after the share price of Corporate Travel Management plunged 27 percent on Wednesday, and will look at the role of VGI Partners in the sudden stock drop.
Generic drug maker Alphapharm says rival Sanofi-Aventis waited to amend its injector pen patent until the heated IP battle between the two firms had commenced, despite knowing about the amendments for three years.
A judge has expressed frustration at the slow pace of the Sydney light rail class action, forcing both parties to commit to a timetable that will push the proceeding more rapidly towards a final hearing.
The founder of a fintech company suing Visa for allegedly abusing its market dominance is flying a Federal Court judge to the UK to preside over the examination of a key but reluctant witness in the case, former Visa boss Rupert Keeley.
UGL knew by April 2014 that there were delays with the Ichthys LNG project, but failed to make required disclosures to shareholders, according to an amended pleading in a shareholder class action against the engineering company.
A judge has approved a $2.5 million penalty against two hearing aid retailers in the consumer regulator’s case alleging the companies targeted vulnerable pensioners with misleading newspaper ads.
Judges do not have the power to approve a class action settlement without first issuing an opt-out notice to group members, the court-appointed contradictor in two shareholder class actions against online fashion retailer Surfstitch told the NSW Supreme Court Thursday.
Private education provider Ashley Services may be close to settling a shareholder class action, according to a court order sending the parties in the case to a second mediation session before the end of the year.
An appeals court has rejected the funder’s commission and legal fees stemming from a $64 million settlement in litigation over the failure of Banksia Securities, but granted approval to the settlement.
Generic Health has shaved two percent off the $25 million damages awarded pharmaceutical giant Bayer in a patent infringement case over Bayer’s blockbuster oral contraceptive, Yasmin, but the discount is a far cry from the 15 percent it sought on appeal.